ReposiTrak, Inc. (TRAK) FY2026 Earnings: Revenue $23M (+3.0%)
TRAK — FY2026 Annual Financial Report Analysis
Full Year · Fiscal year 2026 · Published by Pham Hop
ReposiTrak's fiscal 2026 revenue rose 3% to $23.3M while operating income jumped 26% on lower depreciation and capitalized software costs, a higher tax rate held net income growth to 8.5%, and a new loan-plus-stake bet on SPAR Group adds risk.
Revenue
$23M
+3.0% YoY
Net income
$7.6M
+8.5% YoY
Diluted EPS
$0.39
+11.4% YoY
Operating margin
33.7%
This period vs a year ago
Same period last year
This period
Revenue▲+3.0%
≈$23M
$23M
Net income▲+8.5%
≈$7.0M
$7.6M
Diluted EPS▲+11.4%
≈$0.35
$0.39
Year-ago figures (≈) are worked out from the growth rate the company reported. Each row has its own scale.
ReposiTrak, which sells subscription software that grocery retailers, distributors and their suppliers use to track food-safety paperwork and trace products through the supply chain, grew revenue only 3% in fiscal 2026 (the year to June 30, 2026), to $23.3 million. Operating income still rose 26% to $7.8 million, because costs fell: older assets finished being written down, and the company started capitalizing about $1.0 million of software development spending (recording it as an asset on the balance sheet instead of as an expense). A much higher tax bill then cut net income growth to 8.5%. The year also brought a new and sizeable bet on SPAR Group, a retail-services company, which ReposiTrak now lends to, sells services to, and part-owns.
At a glance
$23.1 million of recurring revenue, up 4%: 99% of sales are subscriptions and support rather than one-off fees, so the revenue base is steady, but it is growing slowly.
33.7% operating margin, up from 27.5%: $0.93 million of the $1.62 million rise in operating income came from lower costs rather than higher sales, and a large part of that is accounting (capitalized software and assets finishing depreciation), not cheaper operations.
About $5.7 million tied up in SPAR at year-end (a $3.0 million loan plus SPAR shares worth $3.5 million), roughly 9% of total assets, rising after July 1 when ReposiTrak bought another 4.7 million shares and took its stake to about 31%.
Results for the year
Metric
FY2026 (to Jun 30, 2026)
FY2025
YoY Change
Revenue
$23.29M
$22.61M
+3.0%
Recurring revenue (subscription & support)
$23.10M
$22.30M
Read 0 community reports on ReposiTrak, Inc., or write your own.Write a report
+3.6%
Non-recurring revenue (setup & training)
$0.19M
$0.31M
-38%
Income from operations
$7.84M
$6.23M
+26.0%
Operating margin
33.7%
27.5%
+6.2 pts
Net income
$7.57M
$6.98M
+8.5%
Diluted EPS
$0.39
$0.35
+11.4%
Effective tax rate
20.5%
8.8%
+11.7 pts
Operating cash flow
$8.22M
$8.42M
-2.3%
Deferred revenue (year-end)
$4.51M
$3.18M
+42.0%
Cash (year-end)
$27.26M
$28.57M
-4.6%
Operating margin is the share of revenue left after running the business, before interest and tax. EPS (earnings per share) is net income available to common shareholders divided by the number of shares.
Where the growth came from, and where it didn't
The company attributes the revenue increase to "growth in recurring subscription revenue across the Company's compliance, supply chain and traceability solutions." It deliberately de-emphasizes one-off work, and setup and training fees fell 38% to $189,000. ReposiTrak reports only one business segment and does not break revenue down by product, so the filing does not show how much of the growth came from the newer Traceability Network versus the older compliance product.
The main regulatory tailwind has been pushed back. The FDA's food traceability rule (FSMA 204, which requires companies handling high-risk foods to record and share tracking data at each step of the supply chain) now has a compliance deadline of July 20, 2028, after a 30-month delay announced in March 2025. The company says adoption "continues to accelerate due to commercial and competitive pressures," pointing to large retailers setting their own, earlier requirements. A 3.6% rise in recurring revenue does not yet show that acceleration in the reported numbers.
Why profit rose much faster than sales
Total operating expense fell 5.7%, from $16.38 million to $15.44 million, and that, not revenue, did most of the work:
Depreciation and amortization fell 48% to $648,000 from $1.25 million because "certain existing property, software and acquired intangible assets became fully depreciated or amortized." That accounts for $604,000, or 37%, of the $1.62 million rise in operating income. It is real (those costs will not come back) but it is a one-time step down, not a trend.
Cost of services fell 10% to $3.31 million, which the company says was "primarily attributable to the capitalization of certain qualifying software development costs that otherwise would have been recognized as expense," partly offset by higher cybersecurity and offshore development costs for Traceability. The balance sheet shows $1.0 million of "capitalized software development in progress," against none a year earlier.
Sales and marketing fell 2% to $5.75 million on fewer marketing staff and lower trade show costs.
General and administrative rose 2% to $5.74 million on personnel costs, stock-based pay, insurance, bad debt and travel.
What the headline numbers hide
Capitalized software flatters the margin. By our arithmetic, had the $1.0 million been expensed as it was in prior years, operating income would have been about $6.84 million, up roughly 10% rather than 26%, and the operating margin about 29% rather than 33.7%. Capitalizing development costs is allowed under the accounting rules once a product is technically feasible, but it moves the cost to future years as amortization.
Tax took back most of the gain. Pre-tax income rose 24% to $9.52 million, but the tax provision nearly tripled to $1.95 million. Fiscal 2025's rate of 8.8% was unusually low, helped by $1.1 million of federal tax credits and a $1.0 million deferred tax adjustment; this year's credits were $357,000 and the rate was 20.5%. That is why net income grew only 8.5%.
Interest is a big part of profit. Interest income on the cash pile was $1.54 million, about 16% of pre-tax income. The company itself notes this "may fluctuate" with rates and with how much cash it holds, and cash is now being redirected toward SPAR.
Cash conversion looks fine but has a hole in it. Operating cash flow of $8.22 million was 1.09 times net income. But $2.33 million of receivables was settled in SPAR shares rather than cash (it is subtracted as a noncash item), and cash flow was propped up by a $1.33 million rise in deferred revenue and a $1.39 million rise in accrued liabilities. After the $1.0 million of capitalized software and $17,000 of equipment, free cash flow was about $7.21 million, down 14% from about $8.40 million.
Receivables and bad debts are rising faster than sales. Net receivables grew 11.6% to $4.61 million against 3% revenue growth, and bad debt expense rose to $950,000 (4.1% of revenue) from $600,000 (2.7%). The allowance for doubtful accounts barely moved ($250,000 vs $242,000), which means most of that expense was write-offs of money the company gave up on collecting.
EPS growth came partly from outside the business. Net income for common shareholders rose 11.8%, faster than net income, because preferred dividends fell to $168,000 from $360,000 as the company redeemed preferred stock. Buybacks ($1.80 million, up from $0.20 million) cut the diluted share count by only 0.8%.
The deferred revenue jump is a good sign, with a caveat. Deferred revenue (cash billed in advance for service not yet delivered) rose 42% to $4.51 million, which normally points to future subscription revenue. The filing does not break out how much of it relates to the new SPAR services agreement.
No guidance. The 10-K gives no revenue or earnings outlook to compare against.
The SPAR bet
This is the largest new item in the filing, and it makes ReposiTrak's accounts harder to read:
A loan: in March 2026 a subsidiary agreed to lend SPAR's operating unit up to $4.0 million at 8% interest, unsecured, maturing March 2029. $3.0 million was advanced by June 30. As a sweetener, SPAR issued ReposiTrak 1 million shares (valued at $0.80 each), with price protection of up to $800,000 in cash if SPAR's stock trades below $0.80. The company is still deciding whether that protection must be accounted for as a separate derivative.
A customer: a one-year services agreement from March 13, 2026, under which ReposiTrak helps SPAR with product development and operations. On May 29 ReposiTrak chose to take $2.33 million owed under it in 3.19 million SPAR shares rather than cash. The filing says no single customer exceeded 10% of fiscal 2026 revenue, but does not say how much SPAR contributed.
A shareholder: at June 30 ReposiTrak owned about 14.8% of SPAR, carried at a fair value of $3.46 million (with a $338,000 unrealized gain booked). On July 1 it agreed to buy another 4.71 million shares for about $3.3 million, mostly with a $2.57 million unsecured note at 6% payable over four years, taking its stake to about 31%.
Being SPAR's lender, supplier and large shareholder at once creates conflicts the company itself flags as a risk. The investment will also change how results look: at 31% ReposiTrak may have to switch to the equity method, reporting its share of SPAR's profits or losses in its own earnings each quarter, which the company says "could increase the volatility" of reported results. For a company whose core business earns about $7.8 million a year in operating income, the combined SPAR exposure after July (roughly $9 million including the new purchase) is a meaningful concentration of risk in one unsecured borrower's performance.
Balance sheet and shareholder returns
ReposiTrak has no bank debt and ended the year with $27.3 million of cash. It returned $5.31 million during the year: $1.80 million in buybacks, $1.87 million redeeming Series B preferred stock and $1.64 million in common dividends ($0.02 per quarter). About $1.7 million of preferred stock remains, which the company intends to redeem by December 31, 2026. After July, it also carries the new $2.57 million SPAR note payable, with $725,000 annual principal payments starting in July 2027.
Takeaway: Underneath a 26% jump in operating profit, the core subscription business grew about 4%. Most of the margin gain came from assets finishing depreciation and from capitalizing $1.0 million of development spending, and the company is now putting a growing slice of its cash into lending to and buying a large stake in SPAR Group, which makes future earnings depend partly on another company's results.
What to watch
Management gives no numeric outlook. The things that will decide whether fiscal 2027 looks better or worse:
Recurring revenue growth. Retailer-driven traceability demand is the growth story; the numbers need to move well above 4% to show it ahead of the 2028 FDA deadline.
SPAR accounting. Whether ReposiTrak moves to the equity method, how the price-protection feature is valued, and whether the remaining $1.0 million of the loan is drawn. Any of these can swing reported profit without touching the software business.
Collections. Another year of receivables and bad debts outpacing revenue would be a warning about customer quality.
Capitalized software. As the $1.0 million starts being amortized once the product is released, part of this year's margin gain will reverse into expense.
This is our first published analysis of ReposiTrak, so there is no earlier outlook of ours to check against.